Pfizer is in value territory, trading at just 10.74X forward earnings with a 5.88% annual dividend yield and over $10 billion in cash after selling $2.4 billion of its HLN position.

Goldman Sachs raises AstraZeneca price target to 16,046 (15,914) pence - 'buy' Barclays raises Standard Chartered price target to 890 (850) pence - 'equal weight' Barclays raises Harbour Energy price ...

The acquired portfolio includes Nicotinell, also known as Nicabate in Australia, Thrive in Canada and Habitrol in New Zealand and Canada.

The experts engaged in critical discussions on the gaps in Oral healthcare access, awareness, and empowerment across India. The gathering focused on developing a sustainable and systematic action plan ...

This summary covers recent developments in health news, from Humana's slumping Medicare plan enrollments impacting future ...

In a report released today, Guillaume Delmas from UBS maintained a Buy rating on Haleon PLC (HLN – Research Report), with a price target ...

Pharmaceutical giant Pfizer Inc. announced on Tuesday that it has reduced its stake in British consumer healthcare company ...

US pharmaceutical giant Pfizer concluded its second sell-down in its consumer healthcare spin-off, Haleon. It raised £2.432bn ...

Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...

The latest health news highlights include Kailera Therapeutics' $400 million funding, potential CVS Health restructuring, ...

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...

Pfizer Inc. ($PFE) has sold its stake worth $3.26 billion in UK-based consumer healthcare company Haleon PLC ($GB:HLN). With ...